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Abstract Tumoural angiogenesis is essential for the
growth and spread of breast cancer cells. Therefore the
aim of this study was to assess the diagnostic performance
of angiogenesis markers in tumours and there reflecting
levels in serum of breast cancer patients. Angiogenin,
Ang2, fibroblast growth factor basic, intercellular adhesion
molecule (ICAM)-1, keratinocyte growth factor (KGF),
platelet-derived growth factor-BB, and VEGF-A were
measured using a FASTQuant angiogenic growth factor
multiplex protein assay. We observed that breast cancer
tumours exhibited high levels of PDGF-BB, bFGF and
VEGF, and extremely high levels of TIMP-1 and Ang-2,
whereas in serum we found significantly higher levels of
Ang-2, PDGF-BB, bFGF, ICAM-1 and VEGF in patients
with breast cancer compared to the benign breast diseases
patients. Moreover, some of these angiogenesis markers
evaluated in tumour and serum of breast cancer patients
exhibited association with standard clinical parameters, ER
status as well as MVD of tumours. Angiogenesis markers
play important roles in tumour growth, invasion and
metastasis. Our results suggest that analysis of angiogenesis
markers in tumour and serum of breast cancer patients
using multiplex protein assay can improve diagnosis and
prognosis in this diseases.
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Background
The formation of new microvessels from preexisting
vessels is necessary for tumor growth, and subsequent
tumour metastasis that involves the interaction of neoplastic
cells with that neovasculature. Angiogenesis depends on
endothelial cell migration, proliferation and differentiation.
The process of new vessel development, partially reflects
the characteristics of the genetically unmodified stromal
tissue of the host, and is involved in three key pathophy-
siologjcal events resulting in the disease progression,
cancer tumour cell proliferation, invasion and hematoge-
nous spread [1–3]. A number of studies have reported that
hematogenous spread of tumour cells is quantitatively
related to intratumoural microvessel density (MVD). These
data shows that the increased MVD is associated with a
higher incidences of metastasis and a poor prognosis in
various malignancies, including breast cancer [4–7].
Usually, angiogenesis is controlled by interactions among
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This interaction is out of balance in cases of malignancy
because of tumor-associated angiogenic factors that can be
produced directly by cancer cells or indirectly by inflam-
matory cells that infiltrate tumor [1–3]. According to
existing data, elevated levels of angiogenesis markers in
both tumour and serum, have been observed in patients
with different types of cancer [8–10]. r, The correlation
between levels of angiogenesis regulated factors, clinical
pathology and prognosis is very significant, especially in
breast cancer [11–13].
In order to elucidate the potential clinical relevance of
the angiogenic activity, we estimated the levels of angio-
genic molecules: bFGF, PDGF, KGF, VEGF, Ang, (Ang-2),
ICAM-1 and TIMP-1 as well in tumour as in the
corresponding serum samples of patients with invasive
breast cancer and benign breast disease. Association
between these markers and clinical parameters of tumour
may have potential value in diagnosis and prognosis of
breast cancer. It is very important since available prognostic
parameters (lymph node status, tumor size, grade of
malignancy, ER, PR and HER2 status) are relatively
inadequate to precisely define the prognosis of individual
patient. Identification of molecular profile of individual
tumors is useful to define subgroups of patients fitting into
different treatment schemes, and it’s considered a most
promising approach in cancer research to improve clinical
outcome. Angiogenesis markers play important role in
tumour growth, invasion and metastasis, and therefore they
seems to be excellent set of candidates for prognostic factors.
Patients
Primary breast tumour tissues (n=127) were obtained from
Caucasian patients during primary curative resection, at the
Department of Surgical Oncology N. Copernicus Hospital
in Lodz, Poland between 2005 and 2009. The subjects were
36 to 84 years old with median age of 62.6 years. All
patients had histologically-confirmed primary breast cancer
(ductal breast carcinoma (n=105) and lobular carcinoma
(n=22)) and benign breast disease (fibroadenoma (n=38)
and ductal hyperplasia (n=16)). Additionally, blood sam-
ples were collected preoperatively from breast cancer
patients (n=76) and women with benign tumor (n=38). A
database comprising detailed clinical data regarding diag-
nosis and histopathological variables of invasive breast
cancer patients was created (Table 1.). None of the breast
cancer patients received neoadjuvant therapy. Written
informed consent had been obtained from all participating
subjects and the study had been approved by the local
Ethics Committee of Medical University of Lodz.
Breast Tissues Sampling
Breast cancer specimens of at least 100 mg were obtained
from the tumor core at the time of surgery from each
patient. The specimens were verified by the study pathol-
ogist to be invasive mammary carcinomas or benign breast
disease. Cell density was assessed in proteinase K digests
by measuring DNA and normalizing it to tissue total
protein. As a normalization measure for the DNA assess-
ments, sample total protein was quantitated. The total
protein and DNA concentration was calculated by the
Qubit™ Quantitation Fluorometer (Invitrogen, California,
USA). Tissue DNA content is a standard indirect measure
of tissue cellularity, therefore, carcinomas specimens and
benign breast disease specimens DNA levels were con-
verted to cell numbers by dividing by 6.9 pg DNA per cell
or by 6.6 pg DNA per cell, respectively. Fragments of
benign lesion tumour (25–35% cellularity) and representa-
tive specimens with more than 70% tumour cells from
breast cancer were then immediately shock frozen and
cryopreserved (−70°C) for subsequent assay preparations.
For FastQuant analysis, tissues of all specimens were
homogenized in the extraction buffer (0.005 M Tris–HCl,
Table 1 The clinical characteristics of patients with invasive breast
cancer
Clinical characteristics Patients (n=127) number/frequencies
Histological grade
Well Dif. 8/0.06
Mod. Dif 55/0.43
Poorly Dif. 64/0.51
Nodal Status
N( −) 71/0.56
N (+) 56/0.44
Distance metastasis
Positive 21/0.16
Negative 106/0.84
Tumoural size
T1 44/0.35
T2 65/0.51
T3/T4 18/0.14
Estrogen receptors
Positive 85/0.67
Negative 42/0.33
Progesterone receptors
Positive 59/0.46
Negative 68/0.54
MVD (n=54)
High (score ≥.26) 22/0.41
Low (score <.26) 32/0.59
810 J. Rykala et al.pH 8) with addition of a cocktail of protease inhibitors (La
Roche, France) in the presence of 0.5% Triton X-100.
Homogenates were centrifugated for 10 min at 10,000 rpm.
The protein concentration of supernatants was calculated by
the Qubit™ Quantitation Fluorometer.
Blood Sampling
Patients sera was obtained by peripheral venous blood
collection which were carried out on the day of surgery.
Blood samples had been collected without anticoagulant
into serum separator vacutainers and allowed to coagulate
for 20 to 30 min at room temperature. Sera were separated
by centrifugation (2,000 rpm, 10 min), and all specimens
were aliquot immediately, frozen, and stored in a −70°C
freezer.
Evaluation of ER and PR
Levels of ER and PR within the tumors of the cases had
been determined by immunohistochemistry as part of the
routine clinical practice. Using the immunohistochemical
assay, tumors were classified as positive if more than 10%
of the cells showed nuclear staining for the receptor. We
obtained the information on ER and PR within the tumors
of the cases from the pathology reports.
FASTQuant® Microspot Assays for Angiogenesis
Factor Quantification
A FASTQuant human angiogenesis array for angiogenin,
Ang2, platelet-derived growth factor (PDGF)-BB, VEGF-
A, fibroblast growth factor basic (FGF-b), keratinocyte
growth factor (KGF), and intercellular adhesion molecule
(ICAM)-1 was run according to the manufacturer’s instruc-
tions (Whatman Schleicher and Schuell, Dassel, Germany).
Built on FAST Slide technology, which is based upon high
protein binding capacity surface chemistry, FAST Quant®
combines the power of array technology with the quanti-
tative nature and high-throughput capabilities of traditional
ELISA. The FAST Slide 3-D nitrocellulose surface is the
industry standard for protein arrays due to its high capacity
and positive influence on protein binding and stability.
Each kit contains four glass slides arranged with 16
nitrocellulose pads on which reference markers and capture
antibody for analytes in that array are dotted in triplicate
using nanodot technology. The kit also includes biotiny-
lated detection antibodies and recombinant antigen stand-
ards for generating a standard curve. The quantitative
analyses of angiogenic molecules were simultaneously
performed under the same conditions using a 7-point mass
standard curve. Briefly, slides were blocked in 70 μl
blocking buffer for 30 min with shaking at room temper-
ature; blocking buffer was removed and 70 μl samples of
breast tissues and serum or standards were added to the
appropriate well and incubated overnight. The slides were
washed three times, then 70 μl biotinylated detection
antibody (Ab) was added and incubated for 1 h. After
another three washes, 70 μl streptavidin-Cy5 solution was
added, the slides were incubated for 45 min in the dark,
washed three times, and allowed to dry. The slides were
imaged using a GenePix scanner (Axon, Molecular Devi-
ces, Workingham, Berks, UK). In order to evaluate the
microarray images we customized the spot intensities
comparison routines available within “The R Project For
Statistical Computing” version 2.5.1 (Fig. 1). A log
transformation of the signal from the samples permitted
comparison to the standard curve to approximate the
concentrations of the angiogenic molecules. The dynamic
range for angiogenin and VEGF was 2.4–2,500 pg/ml and
for all other analytes, was 12.2–12,500 pg/ml.
Assessment of MVD
“Blood Sampling” micro millimeters thick of formaline–
fixed, paraffin embedded tissue were placed on SuperFrost
Plus slides (Menzel-Glaser, Braunschweig, Germany).
These were deparaffinized in xylenes and rehydrated
through graded alcohols. Then, the sections were heated
in DakoCytomation Target Retrival Solution (DAKO,
Glostrup, Denmark), pH 9,0, for 20 min in water bath to
epitope retrieval. After the slides were cooled for 20 min
and incubated for 30 min at room temperature with the
primary monoclonal antibody anti-CD34 (clone QBEnd-10,
1:50 dilution, DAKO, Glostrup, Denmark), and processed
with EnVision+(DAKO, Glostrup, Denmark) system. Sec-
tions were counterstained with haematoxylin, dehydrated
with ethanol, cleared in xylene and sticked with Canada
balsam. Evaluation of number of vessels was done
according to Weidener’s method and its further modifica-
tions [14, 15]. Slides were estimated under 100x magnifi-
cation to take out areas of the biggest condensation of
vessels (hot spots). Next number of vessels was counted
under 400x magnification (HPV, Olympus, BH). As
positive result of imunohistochemistry any single positively
coloured cell or group of cells was evaluated, even in cases
without inside measurement of a vessel. Vessels laing
beside each other were counted independly if only one
stroma cell was found between them. Next mean number of
vessels of 10 HPV was estimated.
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Statistical programs for SigmaStat version 3.5 was used for
data base management and analysis. Quantitative data were
summarized in the form of means, standard deviation,
median and quartiles. t- test and Mann–Whitney test was
used to compare the level of serum and tumour angiogen-
esis marker levels in breast cancer patients and benign
breast disease patients. The median levels of expression of
analyzed angiogenesis markers were compared using
Kruskal-Wallis test according to clinical data (grading,
ER, PR, nodal status, tumoural size, MVD) or analysis of
variance if possible. For correlation analysis Pearson’s
correlation coefficient r and the p-values were determined.
For all statistical analysis, P<0.05 was considered statisti-
cally significant.
Results
Angiogenesis Markers Tumors Levels
A total of 127 samples of primary invasive breast
carcinomas and 54 benign breast disease were analyzed
for 8 angiogenesis markers at the protein level. We
observed that breast cancer tumours exhibited high levels
of PDGF-BB, and VEGF, and extremely high levels of
TIMP-1 and Ang-2, which were over-expressed and
barred performance of test for normality. In contras the
Ang, bFGF, KGF and ICAM-1 were detected in either
benign breast disease or tumour sample on similarly
levels. (Table 2). Next we evaluated, if angiogenesis
markers levels in tumour could be linked to clinical
parameters such as histological grade, tumour size, lymph
node status (Table 3). Positive lymph node status was
linked to elevated of VEGF and ICAM-1 expression.
Distant metastases was associated with high VEGF level.
Additionally ICAM-1 was more abundant in breast cancer
tumour with advanced T stage and we found that VEGF
was significantly over-expressed in ER-positive tumours
compared with ER-negative. We did not observe similar
relationship for PR status. We did not observe any
correlation between histological type and angiogenesis
markers levels.
Angiogenesis Markers Serum Levels
We obtained and analyzed serum samples from 76 breast
cancer patients and 38 benign breast disease patients. We
found significantly higher serum levels of Ang-2, PDGF-
BB, bFGF, ICAM-1 and VEGF in patients with breast
cancer compared to the benign breast diseases patients.
There were no significant differences in serum Ang and
TIMP-1 levels between the both groups of patients
(Table 2). The concentration of KGF in benign breast
disease patients and cancer patients be was undetectable in
most individuals. Regarding bFGF only 23 breast cancer
patients had measurable serum level of bFGF. For this
reason we excluded KGF and bFGF from further analysis.
We performed the same type of analysis to identify if there
was any correlation between serum angiogenesis markers
levels and clinical parameters (Table 4). The analysis
revealed that the largest differences were obtained for
PDGF-BB levels which were very high in serum breast
cancer patient with advanced T stage tumors. Additionally
we demonstrated that patients with lymph node metastases
had higher TIMP-1, ICAM-1 and VEGF serum level. We
observed a trend to higher level of TIMP-1 and VEGF
serum level in patients with distance metastases but it
wasn’t statistic significant. There were no relationship
between remaining serum angiogenesis marker and
clinical-pathologic parameters of breast cancer.
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Fig. 1 The pad of FASTQuant
human angiogenesis array slides
showing a typical array result
for barest cancer tumor sample.
Inserts show the array map for
FAST Quant, D represents spots
containing donkey anti-goat Ig
to act as landing light controls
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MVD was measured in 54 samples and ranged from 0.0 to
110.0, with a mean standard deviation of 25.8±15.8.
Tumors were classified into two groups: those with an
MVD score ≤26 (low MVD; n=32 patients) and ≥.26 (high
MVD; n=22 patients). The breast cancer tumours with rich
network of blood vessels presented significantly higher
Table 2 Average level of angiogenesis markers in tumour and serum of breast cancer patients and benign lesion breast patients. (mean ± SD)
Markers Tumour pg/mg Serum pg/ml or ng/ml
Breast cancer Benign lesion P value Breast cancer Benign lesion P value
Ang 6,673 (795) 5,715 (952) p=0.88 2,341 (764) pg/ml 1,986 (421) pg/ml p=0.67
Ang-2 Overexpress 1,645 (1,185) – 7,111 (1,761) pg/ml 5,409 (2,167) pg/ml p<0.01
KGF 117 (321) 98 (421) p=0.76 421 (122) pg/ml Undetectable –
PDGF-BB 2,476 (7,954) 894 (1,789) p=0.02 7,623 (5,198) pg/ml 5,428 (1,782) pg/ml p=0.02
bFGF 1,759 (485) 1,434 (332) p=0.28 167 (112) pg/ml 22 (98) pg/ml p<0.001
TIMP-1 Overexpress 24,687 (32,885) – 31(38) ng/ml 41 (39)ng/ml p=0.34
ICAM-1 18,760 (7,802) 12,874 (6,743) p=0.06 1,213 (903)ng/ml 327 (78)ng/ml p=0.008
VEGF 1,786 (2,980) 936 (1,873) p=0.04 132 (102) ng/ml 53 (231) ng/ml p=0.009
Table 3 Tumour angiogenesis markers in relation to clinical, pathological and biological characteristics in breast cancer patients. Median
(quartiles)
Clinical variables Ang pg/mg KGF pg/mg PDGF-BB pg/mg bFGF pg/mg ICAM-1 ng/mg VEGF pg/mg
Histological grade
Well Dif. 5,432 (2,171,8,481) 51 (29,287) 8,612 (4,572,10,894) 1,402 (160;3,831) 11,737 (7,924,1,821) 3,271 (233;5,783)
Mod. Dif. 4,189 (3,341;7,761) 44 (11;512) 9,781 (6,608;12,871) 674 (203;1,780) 14,139 (10,989;18,665) 1,043 (613;5,310)
Poorly Dif. 5,633 (3,320;7,195) 88 (14;206) 5,317 (2,678;7,629) 431 (198;3,103) 13,335 (11,467;17,422) 2,115 (764; 7,193)
Nodal Status
N( −) 3,819 (2,624;6,199) 53 (11;176) 8,721 (2,718;10,076) 931 (298;1,765) 11,097 (8,419;15,672) 812 (139;3,203)
N (+) 4,111 (3,719; 9,143) 62 (25;221) 5,929 (1,572;10,842) 754 (195;3,915) 19,920 (13,151;21,981) 4,033 (1,251;9,883)
p=0.004 p=0.003
Distance metastases
M( −) 5,633 (2,088,8,301) 53 (29,512) 6,723 (1,281,10,894) 645 (276;3,354) 12,151 (10,989;19,001) 1,043 (764;6,062)
M (+) 4,187 (2,762,9,143) 75 (25,345) 8,612 (2,678,11,234) 876 (198, 4,234) 17,623 (12,342;19,811) 4,519 (1,251;8,341)
p=0.02
Tumoural size
T1 4,187 (3,668;8,149) 112 (37;222) 5,619 (1,036;9,519) 1,362 (160;2,339) 11,270 (9,880;13,030) 3,732 (1,233;5,761)
T2 5,298 (2,088;7,194) 75 (21;345) 9,522 (648;10,746) 914 (40;3,354) 14,613 (9,975;16,341) 2,387 (587;6,062)
T3/T4 6,199 (2,088;8,172) 86 (31;288) 9,522 (648;10,746) 9,522 (648;10,746) 17,812 (11,725;19,001) 2,101 (542;7,452)
p=0.001
ER
Positive 5,984 (3,327;8,193) 53 (41;305) 4,391 (1,281;8,719) 571 (123;4,165) 16,017 (10,219;19,811) 4,519 (778; 7,538)
Negative 4,812 (2,081;8,481) 38 (11;222) 8,612 (2,804;11,281) 402 (73;2,642) 12,129 (10,635;13,953) 1,218 (135;3,105)
p=0.003
PgR
Positive 7,325 (6,118;9,921) 61 (22,337) 5,522 (1,821;8,933) 691 (47;2,331) 18,542 (9,218;16,841) 3,203 (233;3,609)
Negative 5,409 (4,582;8,816) 32 (21;236) 7,801 (4,193;9,832) 512 (163;1,692) 17,627 (11,827;14,116) 1,716 (657;5,081)
MVD (n=54)
High (≥.26) 7,145 (4,768;8,100) 45 (8;373) 9,519 (8,366;14,076) 266 (23;745) 15,030 (12,259;18,516) 1,946 (564;4,736)
Low (<.26) 4,161 (3,199;7,169) 50 (9;138) 3,238 (1,365;5,622) 1,475 (13;3,909) 11,448 (8,917;15,916) 957 (167;2,987)
p=0.004 p=0.006 p=0.01 p=0.018
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level inversely related with MVD. In serum, similar
correlation was observed only for PDGF-BB.
Correlation Analyses
Pearson’s correlation coefficient and p-values (significance)
were calculated between angiogenesis markers tumour and
serum levels in patients with breast cancer and benign
breast diseases (Table 5). Tumours levels of ICAM-1 and
VEGF displayed a highly significant correlation with serum
levels in breast cancer patients group. No statistically
significant correlation between serum Ang, KGF, PDGF-
BB and bFGF levels as determined by the tumour levels
was found. We also haven’t found any significant correla-
tion between tumour and serum levels of angiogenesis
markers in benign breast diseases patients group.
Discussion
Angiogenesis is critical for tumour growth and progression
and is mediated by a multitude of angiogenic factors and
inhibitors. These factor promote tumour development not
only by activation of intratumural neovascularisation but
also by direct interaction with cancer cells [1–3]. Our
results from breast cancer specimens confirm that hypoth-
esis. We found significantly higher levels of angiogenic
growth factors, PDGF-BB, VEGF as well as angiogenic
mediators TIMP-1 and Ang-2 in breast cancer tumour
compared to benign breast disease tumour. These results
suggest a close association of tissue angiogenic factors and
breast cancer tumour progression.
A number of studies shown that VEGF secretion by
tumor cells is a prerequisite of tumour development, and
that VEGF was required for the initial stages of breast
tumour genesis [16]. Recent data have shown that increased
tumour level of VEGF might be associated with early
relapse and reduced survival in primary breast cancer [17].
Moreover, in breast cancer tumour VEGF level is known to
be correlated with both high MVD and positive nodal
status. Thus, VEGF is suggested to play a key role in the
angiogenic response essential for breast cancer growth, but
it also seems to be involved in metastases. Furthermore,
our data demonstrated a significantly higher VEGF levels
in ER positive tumour, that’s also confirmed by previous
Table 4 Serum angiogenesis markers in relation to clinical, pathological and biological characteristics in breast cancer patients. Median
(quartiles)
Clinical variables Ang pg/mg Ang-2 pg/mg PDGF-BB pg/mg TIMP-1 ng/mg ICAM-1 ng/mg VEGF pg/mg
Histological grade
Well Dif. 3,516 (-;-) 3,004 (-;-) 5,897(-;-) 32.8 (-;-) 916 (-;-) 118 (-;-)
Mod. Dif. 1,651 (343;3,219) 4,731 (2,097;8,654) 3,876(2,544;8,186) 41.6 (10.4;51.2) 911 (578;1,423) 151 (33;312)
Poorly Dif. 2,291 (331;5,617) 3,457 (1,140;21,094) 3,643 (3,159;13,437) 26.1 (14.5;41.7) 777 (701;898) 137 (21;202)
Nodal Status
N( −) 1,761 (351;5,498) 5,394 (1,439;7,504) 5,739 (3,188;8,639) 18.3 (11.7;31.7) 765 (513;1,101) 51 (11;143)
N (+) 1,999 (328;4,316) 3,241 (2,323;9,189) 4,139 (2,317;7,386) 51.0(38.7;52.1) 1,333 (854;1,732) 182 (56;411)
p=0.02 p=0.004 p=0.0007
Distance metastases
M( −) 1,999 (421;5,498) 5,761 (1,439;9,891) 6,442 (2,131,13,437) 26.1 (14.5;54.8) 765 (534;1,871) 154 (21;298)
M (+) 1,651 (341,6,521) 3,457 (1,786;10,938) 8,984 (3,177; 17,871) 48.3 (21.7;62.1) 916 (429;1,415) 198 (31;390)
Tumoural size
T1 1,301 (411;2,651) 4,319 (1,324;11,227) 3,528 (2,131;4,467) 35.1 (15.2;62.1) 823 (675;963) 161 (23;187)
T2 1,765 (341;4,159) 6,412 (2,317;8,415) 6,182 (3,177;11,981) 21.5 (14.8;48.3) 779 (534;1,087) 103(31; 298)
T3/T4 1,287 (421;3,329) 5,761 (1,786;8,761) 8,984 (4,107;17,871) 32.5 (21.7;54.8) 654 (214;1,871) 154(11; 312)
p=0.003
ER
Positive 1,256 (435;3,813) 6,683 (1,928;8,913) 3,651 (2,544;8,193) 27.3 (11.4;52.3) 812 (429;1,126) 123 (41;390)
Negative 1,718 (243;5,068) 4,332 (21,977;10,938) 5,109 (3,620;7,719) 21.5 (8.9;41.4) 701 (568;913) 169 (31;272)
PgR
Positive 1,912 (452;4,935) 5,769 (2,332; 9,891) 4,326 (2,624;7,749) 25.4 (11.5;62.1) 689 (548; 1,415) 198 (29;367)
Negative 1,105 (322;5,284) 4,283 (1,327;12,021) 6,442 (3,957;8,334) 38.3 (14.4;52.3) 869 (622; 8,712) 154 (36;433)
MVD (n=54)
High (≥.26) 1,853 (491;4,163) 6,782 (3,219;12,059) 6,932 (3,645;21,945) 21.5 (10.8;47.5) 791 (577;961) 193 (45;512)
Low (<.26) 1,498 (315;5,441) 8,716 (1,971; 9,815) 4,197 (2,397;7,511) 35.0 (18.7;45.5) 740 (483;919) 144 (21;602)
p=0.002
814 J. Rykala et al.results indicating the 17b-estradiol (E2) factor involved
in direct mechanism of VEGF gene transcription regula-
tion in ER dependent manner [18]. Therefore, different
studies demonstrated negative correlation between VEGF
expression and ER status resulting from BRCA1 activa-
tion [19]. Although we observed only weak correlation
between VGEF serum and tumour levels of breast cancer
patients, we found higher VEGF serum levels for
positive nodal status subjects. Only a few data have
confirmed VEGF serum level as an independent prognos-
tic factor of breast cancer so far. Present study supported
recent findings that VEGF-rich tumours are associated
with breast cancer progression and distance metastases
formation.
The divergence of VEGF as prognostic factor may be
caused by synergistic influence of other angiogenic. In our
work increased levels of PDGF-BB, bFGF in breast cancer
tissue were associated with change in microvessels tumour
count. What’s interesting, PDGF-BB was higher in high
MVD tumor whereas bFGF inversely related to MVD. It is
surprising, since in number of tumours including breast
cancer expression both of these angiogenic factor is
induced by HIF-1 under hypoxia conditions [20]. PDGF
is a potent mitogen and chemoattractant for mesenchymal
cells and fibroblasts which is involved in vessel maturation
through the recruitment of smooth muscle cell and pericytes
to growing vessels during angiogenesis [21]. In breast
cancer tumour PDGF-BB enhances angiogenesis and
growth by stimulating of VEGF expression in tumor
endothelium that increases EC mitogenesis [22]. These
data confirmed our findings because we also observed
association between higher levels of both VEGF and
PDGF-BB and high MVD tumour. Additionally, increased
levels of serum PDGF-BB associated with tumour size
indicating that this factor may be closely related to tumor
growth.
bFGF, next to its paracrine effect, is involved in an
autocrine loop stimulating endothelial cell proliferation
[23]. Regarding bFGF, only 11 breast cancer patients had
measurable serum level and bFGF tumour level was
inversely related to MVD. Previously, similar dependence
have been demonstrated in prostate cancer [24]. However,
in several studies no relationship between bFGF and MVD
has been found. The correlation of serum and tumour bFGF
levels with other clinical parameters are showed no direct
interaction between bFGF expression and angiogenesis in
breast cancer [20, 25, 26].
TIMP-1 is an inhibitor of the MMPs, which may have a
key role in cancer cell dissemination and endothelial cell
migration in angiogenesis [27]. The unexpected association
between high tumor tissue levels of TIMP-1 and a poor
prognosis in breast cancer seems to be a result of cancer-
promoting functions. Recently, it has been demonstrated
that TIMP-1 might be one of the factors involved in such a
stimulation of proliferation and inhibition of apoptosis [28,
29]. Furthermore TIMP-1 which is secreted by fibroblast
may inhibit the production of tumstatin, an antiangiogenic
fragment of collagen IV that is produced by MMP-9
cleavage and thus increased vessel assembly [30]. In our
work, we observed over-expression of TIMP-1 specific for
tumor tissue with no association with other clinical
parameters was estimated. In serum we found significantly
higher TIMP-1 level in breast cancer specimens compared
with benign stage of breast disease. Moreover, we observed
high association between TIMP-1 expression and tumor’s
size as well as high level of MVD. We suggest that these
observation may confirm the mitogenic and proangiogenic
function of TIMP-1 in breast cancer.
ICAM1 has been proposed as a likely candidate for
prognostic factor to breast cancer. Soluble levels of ICAM-
1 in the sera of patients with stage IV breast cancer were
higher than that of healthy controls [31] and patients with
Table 5 Correlation analysis between angiogenesis markers serum and tumour levels in patients with breast cancer and benign breast diseases
Markers Breast cancer patients Benign lesion breast patients
Tumour/serum Tumour/serum
Pearson’s correlation coefficient r P value Pearson’s correlation coefficient r P value
Ang 0.23758 p=0.76 0.26332 p=0.19
Ang-2 Tumoural overexpression – 0.43572 p=0.06
KGF 0.31184 p=0.07 Serum undetectable –
PDGF-BB 0.42718 p=0.08 0.33523 p=0.07
bFGF 0.36373 p=0.34 0.20972 p=0.79
TIMP-1 Tumoural overexpression – 0.30822 p=0.53
ICAM-1 0.59773 p<0.002 0.62917 p<0.01
VEGF 0.69719 p<0.001 0.20102 p=0.43
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facilitates the attachment of carcinoma cells to the
lymphatic endothelial cells and therefore, promote the
micrometastatic in regional lymph node. ICAM-1 ex-
pression was strongly observed around and within the
metastatic region of sentinel lymph node isolated from
breast cancer patients [33]. In this study, we shown a
significantly higher intratumoural ICAM-1 levels in
samples from patients with lymph node metastases, more
advanced T stage and high MVD tumours. These findings
validate hypothesis that ICAM-1 may promote the
development of metastases, therefore ICAM-1 tumour as
well as serum level may be used as poor prognostic factor
in breast cancer patients.
Many investigations have demonstrated that Ang-2 over-
expression is significantly associated with tumourgenesis
and cancer progression [34–36]. Our results confirm these
findings, we observed Ang-2 over-expression in tumour of
breast cancer. Unfortunately we did not show any signifi-
cant differences in Ang-2 serum levels between breast
cancer patients and benign stage of breast diseases patients.
This suggest that not only cancer tumours is a serum Ang-2
source.
Additionally, our results demonstrated that some of
the potent angiogenetic factors of KGF and Ang are
present in both cancer and benign disease of breast so
their levels cannot be associated with any clinical
parameters. It seems that KGF and Ang are involved in
breast cancer development but not in progression of this
disease.
Conclusions
Overall, obtained results confirmed that angiogenetic
factors play important role in tumour growth, invasion
and metastasis so they can be used as prognostic markers of
breast cancer. In recent years, antiangiogenic therapy has
demonstrated significant activity in patients with metastatic
breast cancer. Some patients with previously untreated
metastatic breast cancer, can now recive anti-VEGF
monoclonal antibodies (bevacizumab) combined with stan-
dard chemotherapy doubled progression-free survival [37].
Unfortunately breast cancer treatment is still far from
perfect. The evaluation of angiogenic markers set in tumour
and serum may therefore play important role in selecting
breast cancer patients for combination therapy consisting
individual chosen antyangiogenic drugs.
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